ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: 84% Of Micromet Shares Have Been Tendered

DOW JONES NEWSWIRES Amgen Inc. (AMGN) said nearly 84% of the shares of biotechnology company Micromet Inc. (MITI) have been tendered to its $1.16 billion takeover offer, meeting all the conditions for the acquisition to close. As of the offering's expiration Thursday, about 80 million Micromet shares had been tendered and not withdrawn. An added 3.15 million shares have been tendered by guaranteed delivery. A subsequent offering period is scheduled to expire at 12:00 a.m. EST, at the end of March 6. Amgen launched its bid to acquire Micromet in January with an aim to strengthen Amgen's cancer-drug research pipeline. A Delaware judge declined to block Amgen's purchase of Micromet, the Associated Press reported Thursday. A group of Micromet shareholders had argued that Micromet didn't try hard enough to get a better offer, and sought a preliminary injunction. The judge found that the shareholders didn't show a reasonable likelihood that they would successfully prove their claims, the AP reported. Amgen shares closed at $67.59 Thursday and were inactive premarket. The stock is up 32% in the past 12 months. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
09/29/201609:51:00Amgen, Arrowhead Pharma Agree to Cardiovascular Collaboration
09/29/201607:30:00Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular...
09/28/201616:30:00Amgen Announces Erenumab Significantly Reduces Monthly Migraine...
09/27/201608:32:00Amgen's Myeloma Treatment Study Fails to Meet Primary Endpoint
09/27/201604:00:00Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib...
09/26/201617:00:00Amgen Opens Nomination Process For LabCentral Residency
09/26/201616:00:00Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License...
09/23/201620:12:00FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23/201619:10:00FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23/201618:56:00FDA Approves Amgen's Biosimilar Version of Humira
09/23/201618:04:00FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment O...
09/20/201609:00:00Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV...
09/18/201611:00:00Results From Phase 3 FRAME Study Of Romosozumab Showed Significant...
09/16/201607:34:00Amgen Receives Positive CHMP Opinion For Parsabiv™ (Etelcalcetide) F...
09/15/201616:30:00Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab...
09/14/201616:00:00Amgen To Webcast Investor Call
09/13/201618:22:22Statement of Changes in Beneficial Ownership (4)
09/13/201616:00:00Amgen to Present at the Bank of America Merrill Lynch Global...
09/13/201603:02:00Credit Markets: Apple, Daimler on BOE List -- WSJ
09/12/201616:00:00Bank of England Lists Corporate Bonds Eligible for Purchase

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad